BR0313378A - Formas cristalinas da [4carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-o ctil]-amida do ácido quinoxalina-2-carboxìlico - Google Patents

Formas cristalinas da [4carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-o ctil]-amida do ácido quinoxalina-2-carboxìlico

Info

Publication number
BR0313378A
BR0313378A BR0313378-8A BR0313378A BR0313378A BR 0313378 A BR0313378 A BR 0313378A BR 0313378 A BR0313378 A BR 0313378A BR 0313378 A BR0313378 A BR 0313378A
Authority
BR
Brazil
Prior art keywords
fluorobenzyl
dihydroxy
carboxylic acid
amide
crystalline forms
Prior art date
Application number
BR0313378-8A
Other languages
English (en)
Inventor
John Charles Kath
Zheng Jane Li
Zhengong Bryan Li
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Christopher Stanley Poss
Original Assignee
Pfizer Producs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Producs Inc filed Critical Pfizer Producs Inc
Publication of BR0313378A publication Critical patent/BR0313378A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"FORMAS CRISTALINAS DA [4-CARBAMOIL-1-(3-FLUOROBENZIL)-2,7-DIHIDRóXI-7-METIL-O CTIL]-AMIDA DO áCIDO QUINOXALINA-2-CARBOXìLICO". A presente invenção refere-se com formas cristalinas da [4-carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-octil]-amida do ácido quinoxalina-2-carboxílico, úteis para tratar ou evitar um distúrbio ou condição por antagonismo do receptor CCR1 e com os métodos para a sua preparação e utilização.
BR0313378-8A 2002-08-12 2003-07-31 Formas cristalinas da [4carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-o ctil]-amida do ácido quinoxalina-2-carboxìlico BR0313378A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12
PCT/IB2003/003464 WO2004014875A1 (en) 2002-08-12 2003-07-31 Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide

Publications (1)

Publication Number Publication Date
BR0313378A true BR0313378A (pt) 2005-07-12

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313378-8A BR0313378A (pt) 2002-08-12 2003-07-31 Formas cristalinas da [4carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-o ctil]-amida do ácido quinoxalina-2-carboxìlico

Country Status (22)

Country Link
US (1) US20040072834A1 (pt)
EP (1) EP1539715A1 (pt)
JP (1) JP2005538130A (pt)
AP (1) AP2005003226A0 (pt)
AR (1) AR040839A1 (pt)
AU (1) AU2003250450A1 (pt)
BR (1) BR0313378A (pt)
CA (1) CA2494776A1 (pt)
EC (1) ECSP055588A (pt)
GT (1) GT200300169A (pt)
IL (1) IL166548A0 (pt)
IS (1) IS7674A (pt)
MX (1) MXPA05001781A (pt)
NO (1) NO20050540L (pt)
OA (1) OA12894A (pt)
PA (1) PA8580401A1 (pt)
PE (1) PE20040866A1 (pt)
TN (1) TNSN05035A1 (pt)
TW (1) TW200407316A (pt)
UY (1) UY27928A1 (pt)
WO (1) WO2004014875A1 (pt)
ZA (1) ZA200500768B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079492A1 (es) 2009-12-23 2012-02-01 Ironwood Pharmaceuticals Inc Moduladores de crth2
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (pt) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
TR199902056T2 (xx) * 1997-02-26 2000-01-21 Pfizer Inc. Heteroaril-Heksanoik asit amid t�revleri.
BR9907655A (pt) * 1998-02-05 2000-10-24 Pfizer Prod Inc Derivados de ácido di-hidróxi-hexanóico

Also Published As

Publication number Publication date
GT200300169A (es) 2004-05-12
OA12894A (en) 2006-10-13
IL166548A0 (en) 2006-01-15
CA2494776A1 (en) 2004-02-19
TW200407316A (en) 2004-05-16
JP2005538130A (ja) 2005-12-15
EP1539715A1 (en) 2005-06-15
AR040839A1 (es) 2005-04-20
PE20040866A1 (es) 2004-11-26
TNSN05035A1 (fr) 2007-05-14
ECSP055588A (es) 2005-04-18
IS7674A (is) 2005-01-27
UY27928A1 (es) 2004-03-31
AU2003250450A1 (en) 2004-02-25
WO2004014875A1 (en) 2004-02-19
NO20050540L (no) 2005-03-10
MXPA05001781A (es) 2005-04-25
PA8580401A1 (es) 2004-02-16
AP2005003226A0 (en) 2005-03-31
ZA200500768B (en) 2006-07-26
US20040072834A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
BR0317872A (pt) Medicamentos antiinflamatórios
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0314721A (pt) Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os
BRPI0411900A (pt) compostos antivirais e métodos
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
MY138220A (en) ARYL ANILINE ß2 ADRENERGIC RECEPTOR AGONISTS
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
WO2000002542A3 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
BRPI0415872A (pt) ácidos nucleìcos ligando especificamente à grelina bioativa
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0413584A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
BRPI0509384A (pt) processo de hidrogenação assimétrica para a preparação de um composto ou um sal do mesmo, e, composto ou um sal do mesmo
WO2007076460A3 (en) Substituted thiazole ureas useful as inhibitors of protein kinases
BR0210650A (pt) Tablete, e, uso do mesmo
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
YU78701A (sh) Tretiranje neurotskih poremećaja

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]